Valuation: AN2 Therapeutics, Inc.

Market Cap 170M 154M 142M 129M 243M 15.93B 251M 1.71B 678M 8.55B 636M 623M 27.07B P/E 2026 *
-5.26x
P/E 2027 * -5.84x
Enterprise Value 112M 102M 93.85M 84.77M 160M 10.5B 166M 1.13B 447M 5.63B 420M 411M 17.85B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
83.44%
Yield 2026 *
-
Yield 2027 * -
1 day-1.76%
1 week+11.75%
Current month-1.32%
1 month+32.25%
3 months-25.38%
6 months-5.89%
Current year+292.11%
1 week 4.25
Extreme 4.25
4.75
1 month 3.21
Extreme 3.21
4.9
Current year 1
Extreme 1
7.19
1 year 1
Extreme 1
7.19
3 years 0.87
Extreme 0.87
22.22
5 years 0.87
Extreme 0.87
23.58
10 years 0.87
Extreme 0.87
23.58
Manager TitleAgeSince
Corporate Officer/Principal - 01/02/2017
Chief Executive Officer 58 01/11/2019
Director of Finance/CFO 67 01/11/2019
Director TitleAgeSince
Chairman 58 01/06/2024
Director/Board Member 36 01/11/2019
Director/Board Member 62 01/11/2019
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 A Free

Director

389 0.0010%
10/12/26 A Free

Director

2,465 0.0065%
10/12/26 A Free

Director

2,283 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
-1.76%+11.75%+292.11%-72.79% 170M
-1.29%-3.91%+51.98%+69.06% 65.56B
-1.98%-0.46%+8.56%+90.18% 60.41B
-0.30%+1.00%+23.77%+88.06% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
-0.71%-2.12%+77.42%+58.10% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -0.89%-0.30%+61.10%+151.36% 41B
Weighted average by Cap. -0.93%-1.57%+34.92%+150.23%

Financials

2026 *2027 *
Net sales - -
Net income -36.42M -33.09M -30.58M -27.62M -52.12M -3.42B -53.95M -368M -146M -1.84B -137M -134M -5.81B -45.14M -41.01M -37.89M -34.22M -64.58M -4.24B -66.85M -456M -181M -2.27B -169M -166M -7.2B
Net Debt -57.8M -52.51M -48.52M -43.82M -82.7M -5.43B -85.61M -583M -231M -2.91B -217M -212M -9.23B -31.4M -28.53M -26.36M -23.81M -44.93M -2.95B -46.51M -317M -126M -1.58B -118M -115M -5.01B
Projected Income Statement - Annual - AN2 Therapeutics, Inc.
Logo AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
Employees
-
Date Price Change Volume
16/11/26 $4.470 -1.76% 246,861
13/11/26 $4.550 +2.48% 205,686
12/11/26 $4.440 -0.45% 186,344
11/11/26 $4.460 +3.00% 197,630
10/11/26 $4.330 +8.25% 271,603
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.470USD
Average target price
9.000USD
Spread / Average Target
+101.34%
  1. Stock Market
  2. Stocks
  3. ANTX Stock